Compare RVYL & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | CVKD |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 9.9M |
| IPO Year | 2008 | 2022 |
| Metric | RVYL | CVKD |
|---|---|---|
| Price | $5.56 | $4.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 46.4K | 41.9K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.34 | 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $55,998,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $297.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $4.21 |
| 52 Week High | $8.55 | $17.50 |
| Indicator | RVYL | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 29.91 |
| Support Level | $5.31 | $4.21 |
| Resistance Level | $6.15 | $14.21 |
| Average True Range (ATR) | 0.60 | 0.66 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 60.37 | 1.74 |
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.